Food and Drug Administration, U.S. Department of Health and
FDA researchers have discovered a key mechanism by which
proteins, called chemokines, direct the traffic of immune cells
in response to infections, cancer or other attacks on the body.
These findings, published in the December 1 issue of the
Journal of Experimental Medicine, have important potential
implications for the treatment of AIDS, cancer, heart disease
and other serious medical conditions.
Researchers from FDA's Center for Biologics Evaluation and
Review (CBER) and the University of Sydney discovered how a
protein known as CD26 that is present on the surface of certain
white blood cells influences chemokines and either disables or
The FDA scientists propose that new therapies may be developed
that change the impact that CD26 has on chemokines. These new
treatments may help prevent infection with HIV and other
pathogens, as well as treat or prevent other diseases in which
chemokines have a major role.
The main authors of the study at FDA are Drs. Tamas Oravecz and
Michael Norcross. At the University of Sydney, Dr. Mark
Gorrell is the author.